Latest IR information
IR News
- 2025.10.27
- SymBio Presents Positive Efficacy Data for Brincidofovir in Head and Neck Cancer at ESMO 2025 (Berlin, Germany)
- 2025.10.24
- Notice Regarding Notice of the Large Volume Exercise of the 65th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment
- 2025.10.20
- Patent Obtained for a Groundbreaking Immunoassay with Ultra-High Sensitivity (detection at one part in a trillion)
- 2025.10.15
- SymBio Receives Regulatory Approval in Spain to Proceed with its Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection After HSCT
- 2025.10.07
- SymBio Submits Clinical Trial Application to the UK’s MHRA for the Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection After HSCT